Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer

Article preview from "The Gray Sheet" - January 17, 2011

Abbott will commence a 2,000-patient clinical trial by year end to support U.S. approval of its Absorb drug-eluting bioresorbable vascular scaffold as an alternative to conventional coronary stents following an initial European debut.

Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer

Article preview from "The Gray Sheet" - January 17, 2011

Abbott will commence a 2,000-patient clinical trial by year end to support U.S. approval of its Absorb drug-eluting bioresorbable vascular scaffold as an alternative to conventional coronary stents following an initial European debut.

The firm announced CE mark clearance Jan. 10, making Absorb the first drug-eluting bioresorbable vascular scaffold available to treat coronary artery disease. Abbott expects to submit a PMA by 2015.

Unlike current stents on the market made of metal, Absorb – previously referred to as BVS – is made of polylactide polymer. Since the everolimus-eluting scaffold dissolves over the course of two years as coronary lesions heal, the device could eliminate the potential for certain long-term adverse events associated with conventional drug-eluting metal stents, such as the formation of blood clots, and the need for blood clot medication, Abbott said.

To purchase this article online or get it FREE when you subscribe to "The Gray Sheet".

Plus:

To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512